CORCEPT-CORT125134-557-BELLA
Phase II
OPEN TO ACCRUAL
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
GOG-3096-DAIICHI-DS6000-109
Phase II/III
OPEN TO ACCRUAL
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-Dxd), a CDH6-Directed Antibody-Drug Conjugate, in Subjects with Platinum-Resistant, High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer